After hours: March 14 at 5:59:16 PM EDT Loading Chart for NABL ...

In a report released yesterday, Matthew Hedberg from RBC Capital maintained a Buy rating on N-able (NABL – Research Report), with a price target of $10.00. The company’s shares closed ...

Mar. 12, 2025 — A new study analyzing diet, average plasma sugar levels and cancer prevalence in some 273 vertebrate species showed surprising results. The study found no significant link ...

Jan. 28, 2025 — A team of stem cell scientists have successfully used embryonic stem cell engineering to create a bi-paternal mouse -- a mouse with two male parents -- that lived until adulthood.

DOM.MC Global Dominion Access, S.A.

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

Results of a phase I/II clinical trial of CALEC, limbal epithelial cell grafts generated by an innovative and rigorously standardized manufacturing protocol, showing safety and feasibility for ...

N-able, Inc. (NYSE:NABL), a global software company helping IT services providers deliver security, data protection as-a-service and unified endpoint management, today announced that its Board of ...

and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise ...